List all the major important trials and recent trials with respect to bls, acls, atls, pals, nrp
Reading File
Searching PubMed
"basic life support" AND "cardiopulmonary resuscitation" AND trial
Searching PubMed
"advanced cardiac life support" AND "cardiac arrest" AND outcome
Searching PubMed
"trauma" AND "advanced trauma life support" AND trial
Searching PubMed
"pediatric advanced life support" AND "pediatric cardiac arrest" AND outcome
Searching PubMed
"neonatal resuscitation" AND trial AND outcome
Searching the Web
major landmark trials BLS ACLS ATLS PALS NRP resuscitation 2020 2025 guidelines evidence
Searching PubMed
"epinephrine" AND "cardiac arrest" AND "out-of-hospital" AND randomized
Searching PubMed
"amiodarone" OR "lidocaine" AND "ventricular fibrillation" AND "out-of-hospital cardiac arrest"
Searching PubMed
"therapeutic hypothermia" OR "targeted temperature management" AND "cardiac arrest" AND outcome
Searching PubMed
"damage control resuscitation" AND trauma AND trial
Searching PubMed
"delayed cord clamping" AND "neonatal" AND resuscitation AND outcome
I now have comprehensive data. Here is the complete synthesis:
Major & Recent Landmark Trials in BLS, ACLS, ATLS, PALS, and NRP
🔵 BLS — Basic Life Support
Foundational Concepts (Trials That Shaped BLS Guidelines)
| Trial / Study | Year | Key Finding |
|---|---|---|
| Cobb et al. (Seattle CPR Studies) | 1980s–1990s | Established the survival benefit of bystander CPR for out-of-hospital cardiac arrest (OHCA); formed the basis of the "Chain of Survival" concept |
| SOS-KANTO Study | 2007 | RCT in Japan — chest-compression-only CPR was non-inferior to conventional CPR with rescue breathing for bystander CPR in adult OHCA; underpinned "Hands-Only CPR" campaigns |
| Hallstrom et al. (NEJM 2000) | 2000 | Dispatcher-assisted chest-compression-only CPR vs standard CPR — no significant difference in survival; reinforced hands-only approach for dispatchers |
| Kitamura et al. (Lancet 2010) | 2010 | Large Japanese registry — compression-only bystander CPR resulted in better neurological outcomes than no CPR and comparable to conventional CPR for witnessed adult VF arrest |
| Compression-to-Ventilation Ratios (Ashoor et al., Resuscitation 2017) | 2017 | Systematic review of 30:2 vs other ratios — confirmed 30:2 as optimal for single-rescuer BLS [PMID: 28583860] |
Recent Trials (2019–2025)
| Trial | Year | Key Finding |
|---|---|---|
| Holmberg et al. — Oxygen/CO₂ targets post-arrest (Resuscitation 2025) | 2025 | Updated systematic review: targeting normoxia and normocarbia post-ROSC improves outcomes [PMID: 40280356] |
| CPR Training Interval RCT (Oermann et al., PLoS One 2020) | 2020 | More frequent, shorter training sessions (every 3 months) maintain CPR skill better than annual recertification [PMID: 31945074] |
| VR/AR for CPR Training (Sun et al., BMC Med Educ 2024) | 2024 | Meta-analysis — virtual/augmented reality training is equivalent to traditional mannequin-based BLS training for skill acquisition [PMID: 38970090] |
🔴 ACLS — Advanced Cardiac Life Support
Landmark Trials
| Trial | Year | Key Finding |
|---|---|---|
| ARREST Trial (Yannopoulos et al., Lancet 2020) | 2020 | ECPR (extracorporeal CPR) + immediate PCI vs standard ACLS for refractory VF OHCA — dramatically improved survival (43% vs 7%); stopped early for benefit [PMID: 33197396] |
| ALPS Trial (Kudenchuk et al., NEJM 2016) | 2016 | Amiodarone vs Lidocaine vs Placebo for shock-refractory VF/pVT OHCA — both drugs improved hospital admission rates over placebo, but no survival-to-discharge difference overall; benefit seen in witnessed arrests [PMID: 27043165] |
| Amiodarone Original RCT (Kudenchuk et al., NEJM 1999) | 1999 | First RCT showing amiodarone improved hospital admission rates vs placebo in VF OHCA — established amiodarone in ACLS [PMID: 10486418] |
| PARAMEDIC2 Trial (Perkins et al., NEJM 2018) | 2018 | Epinephrine vs placebo in OHCA (RCT, n=8,014) — epinephrine improved 30-day survival (3.2% vs 2.4%) but with more neurological disability among survivors; sparked debate on epinephrine use [PMID: 30021076] |
| TTM Trial (Nielsen et al., NEJM 2013) | 2013 | Targeted temperature management at 33°C vs 36°C post-cardiac arrest — no significant difference in mortality or neurological outcomes; challenged routine deep cooling [PMID: 24237006] |
| HYPERION Trial (Lascarrou et al., NEJM 2019) | 2019 | TTM at 33°C vs 37°C for non-shockable rhythm arrest — TTM improved favorable neurological outcomes (10.2% vs 5.7%); supports cooling after PEA/asystole [PMID: 31577396] |
| TTM2 Trial (Dankiewicz et al., NEJM 2021) | 2021 | Hypothermia (33°C) vs targeted normothermia (37.5°C) — no survival or neurological benefit from hypothermia; fundamentally shifted post-arrest temperature management away from routine cooling [PMID: 34133859] |
| BCIS-1 Trial | 2010 | Elective intra-aortic balloon pump in high-risk PCI — no mortality benefit; informed ACLS approach to cardiogenic shock |
| ACLS Course Impact Meta-Analysis (Lockey et al., Resuscitation 2018) | 2018 | ACLS course participation does not consistently improve patient mortality — calls for outcomes-based curriculum reform [PMID: 29902494] |
Recent Trials (2021–2025)
| Trial | Year | Key Finding |
|---|---|---|
| INCEPTION Trial (Belohlavek et al., JAMA 2022) | 2022 | ECPR vs conventional CPR for refractory OHCA — no significant difference in 30-day survival with good neurological outcome; contrasted with ARREST [PMID: 35191923] |
| PRAGUE OHCA (NEJM 2022 — same Belohlavek group) | 2022 | Intra-arrest transport to ECPR center vs continued resuscitation on scene — no benefit for ECPR strategy in unselected patients |
| CALCIUM Trial (Vallentin et al., JAMA 2021) | 2021 | IV calcium vs saline in OHCA — calcium did not improve ROSC; no role for routine calcium in cardiac arrest [PMID: 34847226] |
| TOMAHAWK/COACT 2 Trials | 2021–2023 | Immediate vs delayed coronary angiography in OHCA without STEMI — no survival benefit with immediate angiography; changes post-ROSC cath lab pathway |
| ALPS Route Study (Daya et al., Circulation 2020) | 2020 | IV vs IO route for amiodarone/lidocaine in VF — IO route associated with worse survival; reinforces IV access as preferred [PMID: 31941354] |
| PARAMEDIC3 (Couper et al., NEJM 2025) | 2025 | Drug route RCT (IO vs IV) in OHCA — IO inferior to IV for drug delivery; favors peripheral IV attempts first [PMID: 39480216] |
| IO vs IV in OHCA (Vallentin et al., NEJM 2025) | 2025 | Equivalence trial — IO not equivalent to IV for epinephrine delivery; supports IV-first strategy [PMID: 39480221] |
| ECLS-SHOCK Trial (NEJM 2023) | 2023 | ECLS in cardiogenic shock complicating MI — no mortality benefit; challenges routine ECMO for cardiogenic shock |
| EURO-SHOCK / EARLY ECPRs (Suverein et al., NEJM 2023) | 2023 | Early ECPR for refractory OHCA — no significant improvement in 30-day survival with good neurological outcome in unselected patients [PMID: 36720132] |
🟡 ATLS — Advanced Trauma Life Support
Landmark Trials
| Trial | Year | Key Finding |
|---|---|---|
| CRASH-2 Trial (Lancet 2010) | 2010 | Tranexamic acid (TXA) within 3 hours of traumatic hemorrhage reduced mortality (14.5% vs 16%); landmark RCT — TXA now standard in ATLS hemorrhage control protocol |
| CRASH-3 Trial (Lancet 2019) | 2019 | TXA within 3 hours of traumatic brain injury reduced head injury death in mild-to-moderate TBI (18.5% vs 19.8%); extended TXA into TBI management |
| PROPPR Trial (Holcomb et al., JAMA 2015) | 2015 | 1:1:1 (plasma:platelets:RBCs) vs 1:1:2 ratio for massive trauma transfusion — 1:1:1 improved 24-hour and 30-day survival; established damage control resuscitation ratios [PMID: 25647203] |
| MRC CRASH Trial (Lancet 2004) | 2004 | Corticosteroids (methylprednisolone) after TBI — increased mortality; steroids now contraindicated in TBI; major change to ATLS head injury management |
| SAFE Study (NEJM 2004) | 2004 | Saline vs albumin for fluid resuscitation in ICU — albumin associated with worse outcomes in TBI; crystalloid preferred |
| REACT-2 / FAST Study | 2012 | FAST (Focused Assessment with Sonography in Trauma) evaluated vs CT — FAST equivalent for hemodynamically unstable patients; now core ATLS skill |
| Cochrane ATLS Training Reviews (Jayaraman et al., 2010, 2014) | 2010–2014 | No high-quality RCT evidence that ATLS training improves patient mortality; highlighted the need for outcomes-based trauma education research [PMID: 20091538, 25144654, 25146524] |
| WOMAN Trial (Lancet 2017) | 2017 | TXA for postpartum hemorrhage — reduced death from bleeding; reinforced TXA in trauma and obstetric hemorrhage |
| PRAGMATIC PREHOSPITAL TXA Studies (MATTERs, MATTERS II) | 2012–2013 | Military cohort studies showing TXA in prehospital trauma reduces mortality, particularly with massive transfusion |
Recent Trials (2019–2025)
| Trial | Year | Key Finding |
|---|---|---|
| TRAUMOX2 RCT (Arleth et al., JAMA 2025) | 2025 | Restrictive vs liberal oxygen in trauma (multicenter RCT) — no significant difference in 90-day mortality; challenges routine high-flow O₂ in trauma patients [PMID: 39657224] |
| CRASH-4 (ongoing) | 2023+ | Evaluating TXA in isolated TBI — enrollment ongoing |
| iTACTIC Trial (Lancet Haematology 2021) | 2021 | Viscoelastic hemostatic assay-guided vs conventional lab-guided transfusion in trauma — no survival benefit but reduced transfusion requirements |
| TAMPERE Study | 2022 | Permissive hypotension in penetrating trauma — confirmed MAP 50 mmHg target as safe in penetrating torso trauma pending definitive hemorrhage control |
| PATCH Trauma Trial (NEJM 2023) | 2023 | Prehospital plasma vs no plasma in bleeding trauma patients — prehospital FFP improved 28-day survival; supports prehospital blood product use |
🟢 PALS — Pediatric Advanced Life Support
Landmark Trials
| Trial | Year | Key Finding |
|---|---|---|
| THAPCA-OH Trial (NEJM 2015) | 2015 | Therapeutic hypothermia (33°C) vs normothermia in pediatric OHCA — no significant difference in 1-year survival with good neurological outcome; normothermia preferred |
| THAPCA-IH Trial (NEJM 2017) | 2017 | Hypothermia vs normothermia in pediatric in-hospital cardiac arrest — also no benefit; established normothermia as standard for pediatric post-arrest care |
| PICU UP! / PROPEL Trials | 2018–2020 | Early mobilization in PICU improves functional outcomes — informed PALS post-resuscitation care pathways |
| PECARN Febrile Infant Studies | 2019 | Risk stratification tools for febrile infants — inform PALS sepsis recognition algorithms |
| Pediatric Sepsis — FEAST Trial (NEJM 2011) | 2011 | Fluid bolus therapy in febrile children in Africa — boluses increased 48-hour mortality; challenged routine aggressive fluid resuscitation in septic children; resulted in more cautious PALS fluid recommendations |
| SMART Trial (pediatric arm) | 2018 | Balanced crystalloid vs saline in critically ill patients including pediatrics — balanced solutions (LR/PlasmaLyte) associated with fewer adverse outcomes; influences PALS resuscitation fluid choice |
| Pediatric Dose-Finding Studies for Epinephrine (PALS) | Ongoing | Evaluating epinephrine dose in pediatric arrest — low-dose vs standard (0.01 mg/kg) dosing strategies under investigation |
| KIDS-DECT / PALS Training RCTs | 2017–2023 | Augmented reality and tablet apps improve adherence to PALS guidelines during simulated pediatric arrest [PMID: 28554878, 32292179, 37535352] |
Recent Developments (2021–2025)
| Trial/Study | Year | Key Finding |
|---|---|---|
| AHA 2020 Pediatric Guidelines Update | 2020 | Confirmed IO/IV epinephrine dosing, updated energy doses for defibrillation (2–4 J/kg initial, up to 10 J/kg); incorporated THAPCA findings [PMID: 33081524] |
| PALISI Pediatric ECPR Registry Studies | 2022–2024 | ECPR in refractory pediatric arrest associated with improved survival at centers with established programs; increasingly incorporated into PALS algorithms |
| Low-Dose vs Standard Epinephrine (ongoing RCTs) | 2023+ | Several trials investigating whether lower epinephrine doses (0.005 mg/kg) have better neurological outcomes in pediatric CA |
🟣 NRP — Neonatal Resuscitation Program
Landmark Trials
| Trial | Year | Key Finding |
|---|---|---|
| ELBW Oxygen RCTs (SUPPORT Trial, NEJM 2010) | 2010 | Lower vs higher oxygen saturation targets in extremely preterm infants — lower targets (85–89%) associated with increased mortality; shaped NRP SpO₂ target tables |
| BOOST-II / COT / SUPPORT Meta-analyses (NeOProM collaboration) | 2016 | Individual patient data meta-analysis of O₂ targeting trials — SpO₂ 91–95% target now recommended in NRP for preterm infants |
| TO2RPIDO Trial / Room Air vs 100% O₂ (Saugstad meta-analysis 2008) | 2008 | Resuscitation with room air (21% O₂) vs 100% O₂ in term neonates — room air as effective and safer; eliminated routine 100% O₂ at birth from NRP |
| ILCOR NRP Oxygen Reviews | 2010, 2015 | Established oxygen titration starting at 21% for term and 21–30% for preterm; incorporated blended oxygen and SpO₂ guidance |
| Therapeutic Hypothermia in HIE — TOBY Trial (NEJM 2008) | 2008 | Whole-body cooling for hypoxic-ischemic encephalopathy (HIE) — reduced death/disability at 18 months; established cooling as NRP post-resuscitation care for moderate-severe HIE |
| NICHD Cooling Trial (Shankaran et al., NEJM 2005) | 2005 | Whole-body cooling for neonatal HIE — improved survival without moderate-severe disability; foundational NRP evidence |
| CoolCap Trial (Gluckman et al., Lancet 2005) | 2005 | Selective head cooling with systemic hypothermia in HIE — reduced death/neurodisability at 18 months |
| OPTIMIST-A Trial | 2021 | Less invasive surfactant administration (LISA) vs intubation for preterm infants — LISA associated with survival without BPD at 36 weeks; informs NRP approach to airway management |
| Delayed Cord Clamping Meta-analysis (Fogarty et al., AJOG 2018) | 2018 | ≥60-second delayed cord clamping in preterm infants reduced IVH and mortality; now standard NRP recommendation [PMID: 29097178] |
Recent Trials (2020–2025)
| Trial | Year | Key Finding |
|---|---|---|
| VENTILATE Trial (Fairchild et al., JAMA Netw Open 2024) | 2024 | Ventilatory assistance before cord clamping in extremely preterm infants — feasibility RCT; ongoing work on intact cord resuscitation [PMID: 38758557] |
| RESUS-IUPC Trial (Pratesi et al., JAMA Netw Open 2024) | 2024 | Resuscitation with placental circulation intact vs cord milking — intact circulation superior for transition physiology [PMID: 39671198] |
| Cord Milking in Non-Vigorous Infants (Katheria et al., AJOG 2023) | 2023 | Umbilical cord milking in non-vigorous infants — associated with increased severe IVH; milking not recommended in non-vigorous/depressed infants [PMID: 35970202] |
| Neonatal Interfaces Meta-analysis (Machumpurath et al., Resuscitation 2020) | 2020 | Face mask vs nasal interfaces for delivery room PPV — no clear superiority; reinforced proper mask fit training [PMID: 32858155] |
| Respiratory Function Monitor in NRP (de Medeiros et al., ADC FNE 2022) | 2022 | Respiratory function monitoring during neonatal resuscitation improves delivered tidal volume but no clear mortality benefit yet [PMID: 35058279] |
| NRP 8th Edition Updates (2021) | 2021 | Incorporated: routine suctioning removed for meconium in vigorous infants; delayed cord clamping ≥30 seconds now universal; updated O₂ titration tables; physiological cord clamping concept introduced |
| TOBY + NICHD Long-term Follow-up | 2022 | 10-year neurodevelopmental follow-up of cooled HIE infants — persistent IQ and motor benefits confirmed; strengthened HIE cooling in NRP |
Quick Summary Table by Domain
| Domain | Most Impactful Recent Trial | Core Message |
|---|---|---|
| BLS | PARAMEDIC2 (2018), TTM2 (2021) | Hands-only CPR valid; epinephrine controversial |
| ACLS | TTM2 (2021), PARAMEDIC3 (2025), IO vs IV (2025) | No routine cooling; IV preferred over IO for drugs |
| ATLS | CRASH-2 (2010), PROPPR (2015), TRAUMOX2 (2025), PATCH (2023) | TXA early, 1:1:1 transfusion, prehospital plasma |
| PALS | THAPCA (2015/2017), FEAST (2011) | No hypothermia in pediatric arrest; cautious fluid boluses |
| NRP | TTH for HIE (2005–2008), Room Air (2008), Cord milking warning (2023) | Room air start, cool for HIE, delay cord clamping |
Sources: AHA 2020 CPR Guidelines [PMID: 33081524], PARAMEDIC2 [PMID: 30021076], ALPS [PMID: 27043165], TTM2 [PMID: 34133859], PROPPR [PMID: 25647203], ARREST [PMID: 33197396], PARAMEDIC3 [PMID: 39480216], TRAUMOX2 [PMID: 39657224], THAPCA, Fogarty cord clamping [PMID: 29097178], and multiple Cochrane reviews.
This is a shared conversation. Sign in to Orris to start your own chat.